Mikhail Blagosklonny is a distinguished scientist famously known for his research in cancer and aging. Mikhail is also a professor of oncology at the Roswell Cancer Institute in New York. He earned his MD in internal medicine from the First Pavlov State Medical University of St. Petersburg. He later received his Ph.D. in experimental medicine and cardiology from the same university. In 2002, he was promoted to become an associate professor at New York Medical College. In 2009, he joined Roswell Cancer Institute. Prior to joining Roswell Cancer Institute, Mikhail served as a senior scientist at the Ordway Research Institute.

Mikhail Blagosklonny is one of the most experienced oncologists. From holding different positions in various reputed organizations, he has gained a wealth of experience and skills. His research primarily targets biogerontology, cancer, targeted cancer therapies and anti-aging drugs. Mikhail believes that the number of old people with chronic degenerative conditions such as cancer and age will keep on increasing and, therefore, the need for well-thought research in anti-aging drugs and cancer treatment. View Mikhail’s profile on Loop

TOR Hypothesis

Mikhail is globally recognized for formulating TOR signaling through Rapamycin, which a cancer drug with anti-aging properties and a potential to prolong human life. Rapamycin is used to coat coronary stents reducing the possibility of organ rejection during an organ transplant. Mikhail firmly believes that cancer can be controlled by controlling the aging process of the human body. He is considered one of the most prominent advocates of Rapamycin longevity research.

Mikhail at Roswell Park Cancer Institute

In his research at Roswell Cancer Institute, the oncology professor researched deeply on therapies that can protect healthy and normal from getting damaged. He also devoted much of his time in studying on mechanisms of aging and anti-aging.

Editorial Activities

Mikhail has published over 300research papers and book chapters. Most of his publications range from molecular biology to clinical investigations. In most of his articles, Mikhail has written about mitosis, drug resistance, apoptosis, tumor suppressors, signal transduction, and oncogenesis. He is the founding editor and editor in chief of Cell Cycle and the co-editor of the Aging, Oncoscience, and Oncotarget. Read more about Mikhail at LinkedIn.com